论文部分内容阅读
It is generally accepted that efficient siRNA delivery in vivo is the major hurdle in development of siRNA therapeutics.To overcome this obstacle,we have concentrated on developing siRNA therapeutics for indications involving cells/tissues to which naked siRNA can be readily delivered.Quark currently has three different synthetic siRNA product candidatesthat are being evaluated in clinical trials for five different disease indications.